A PSA test in midlife could help to identify men at low risk of prostate cancer, supporting screening strategies and reducing overdiagnosis.

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Prostate cancer kills around 3,900 Australians a year.

News that former President Joseph Biden has advanced prostate cancer has revived long-standing questions about the benefits versus the harms of a blood test that screens for the most commonly ...

In real-world patients with mHSPC, a PSA cutoff of 0.2 ng/mL after 6 to 12 months of intensified hormone therapy predicts survival outcomes. An absolute PSA level of 0.2 ng/mL or more at 6 to 12 ...

Please provide your email address to receive an email when new articles are posted on . The task force issued guidance in 2012 advising against PSA testing for all men. The panel later reversed its ...

As the magnitude of PSA decline during 177Lu-PSMA-617 therapy for mCRPC increases, the risks for radiographic progression and all-cause mortality decreases. The magnitude of PSA decline at 12 weeks ...